间变性淋巴瘤激酶(ALK)的重排与几种癌症疾病有关。由于对现有ALK抑制剂的耐药性不断发展,因此需要新型的,结构上不相关的抑制剂。通过支架跳跃策略,将6,8-二取代的嘌呤设计为类似的抑制ALK的噻吩并[3,2- d ]嘧啶的类似物。尽管新的标题化合物确实在亚微摩尔浓度下抑制了ALK和几个ALK突变体,但它们的水溶性差。
protection factor (SPF) in vitro, and 2,2-diphenyl-1-picrylhydrazyl (DPPH) and ferric ion reducing antioxidant power (FRAP) tests for evaluating the antioxidant activity of the more potent compounds. Among them, 8-(2,5-dihydroxyphenyl)-7H-purin-6-ol (compound 26) proved to be a good radicalscavenger and is also endowed with broad-spectrum UVA filtering capabilities, suitable for further development
Ag support on silica has been used as an effective heterogeneouscatalyst for the facile synthesis of chloro‐8‐substituted‐9H‐purine derivatives via the one‐pot reaction of 6‐chloro‐pyrimidines and substituted acids. The title compounds were formed as excellent yields with short reaction time under eco‐friendly conditions. The prepared catalyst (Ag/SiO2) can be reused for a number of times with insignificant
Rearrangements of anaplastic lymphoma kinase (ALK) are associated with several cancer diseases. Due to resistance development against existing ALK-inhibitors, new, structurally unrelated inhibitors are required. By a scaffoldhoppingstrategy, 6,8-disubstituted purines were designed as analogues of similar ALK-inhibiting thieno[3,2-d]pyrimidines. While the new title compounds indeed inhibited ALK and
间变性淋巴瘤激酶(ALK)的重排与几种癌症疾病有关。由于对现有ALK抑制剂的耐药性不断发展,因此需要新型的,结构上不相关的抑制剂。通过支架跳跃策略,将6,8-二取代的嘌呤设计为类似的抑制ALK的噻吩并[3,2- d ]嘧啶的类似物。尽管新的标题化合物确实在亚微摩尔浓度下抑制了ALK和几个ALK突变体,但它们的水溶性差。